GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

N/ATerminatedNCT01355003

Merck Sharp & Dohme LLC1,080 enrolled

Overview

This study will collect safety information on the use of GARDASIL™ in the Philippines.

Study Type

OBSERVATIONAL

Enrollment

1,080

Sex: ALLMin age: 9 YearsMax age: 46 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Received GARDASIL™

Number of participants with adverse events following any dose of vaccine

Time frame: At least 30 days following any vaccine dose

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.